Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tetradecylthioacetic acid 是一种合成脂肪酸,在 β 位具有硫取代。这种修饰使 TTA 无法进行完全的 β-氧化并增加其生物活性,包括激活过氧化物酶体增殖物激活受体 (PPAR),优先选择 PPARα。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 185 | 现货 | ||
5 mg | ¥ 413 | 现货 | ||
10 mg | ¥ 663 | 现货 | ||
25 mg | ¥ 1,160 | 现货 | ||
50 mg | ¥ 1,830 | 现货 | ||
100 mg | ¥ 2,820 | 现货 | ||
200 mg | ¥ 3,970 | 现货 | ||
500 mg | ¥ 6,450 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 397 | 现货 |
产品描述 | Tetradecylthioacetic acid is a synthetic fatty acid with a sulfur substitution in the β-position. This modification renders TTA unable to undergo complete β-oxidation and increases its biological activity, including activation of peroxisome proliferator activated receptors (PPARs) with preference for PPARα. |
体内活性 | Mice receiving HFD supplemented with 0.75% (w/w) TTA had significantly lower body weights compared to mice fed the diet without TTA. Plasma triacylglycerol (TAG) was reduced 3-fold with TTA treatment, concurrent with increase in liver TAG. Total cholesterol was unchanged in plasma and liver. However, TTA promoted a shift in the plasma lipoprotein fractions with an increase in larger HDL particles. Histological analysis of the small intestine revealed a reduced size of lipid droplets in enterocytes of TTA treated mice, accompanied by increased mRNA expression of fatty acid transporter genes. Expression of the cholesterol efflux pump Abca1 was induced in the small intestine, but not in the liver. Scd1 displayed markedly increased mRNA and protein expression in the intestine of the TTA group[1]. |
分子量 | 288.49 |
分子式 | C16H32O2S |
CAS No. | 2921-20-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (207.98 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.4663 mL | 17.3316 mL | 34.6632 mL | 86.6581 mL |
5 mM | 0.6933 mL | 3.4663 mL | 6.9326 mL | 17.3316 mL | |
10 mM | 0.3466 mL | 1.7332 mL | 3.4663 mL | 8.6658 mL | |
20 mM | 0.1733 mL | 0.8666 mL | 1.7332 mL | 4.3329 mL | |
50 mM | 0.0693 mL | 0.3466 mL | 0.6933 mL | 1.7332 mL | |
100 mM | 0.0347 mL | 0.1733 mL | 0.3466 mL | 0.8666 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tetradecylthioacetic acid 2921-20-2 DNA Damage/DNA Repair Metabolism PPAR Peroxisome proliferator-activated receptors β-Oxidation inhibit fatty acid oxidation Inhibitor 2-(Tetradecylthio)acetic acid hypolipidemia inhibitor